The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

Lotte M. Knapen*, Rutger H. T. Koornstra, Johanna H. M. Driessen, Bas van Vlijmen, Sander Croes, Stein Schalkwijk, Angela Colbers, Winald R. Gerritsen, David M. Burger, Frank de Vries, Nielka P. van Erp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)363-370
Number of pages8
JournalTargeted Oncology
Volume13
Issue number3
DOIs
Publication statusPublished - Jun 2018

Keywords

  • TUMOR RESPONSE
  • OPEN-LABEL
  • PHARMACOKINETICS
  • TOLERANCE
  • SURVIVAL
  • EFFICACY
  • SAFETY

Cite this

Knapen, Lotte M. ; Koornstra, Rutger H. T. ; Driessen, Johanna H. M. ; van Vlijmen, Bas ; Croes, Sander ; Schalkwijk, Stein ; Colbers, Angela ; Gerritsen, Winald R. ; Burger, David M. ; de Vries, Frank ; van Erp, Nielka P. / The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma : a Retrospective Cohort Study. In: Targeted Oncology. 2018 ; Vol. 13, No. 3. pp. 363-370.
@article{c416e48e8a39498a97a25236798d82b3,
title = "The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study",
keywords = "TUMOR RESPONSE, OPEN-LABEL, PHARMACOKINETICS, TOLERANCE, SURVIVAL, EFFICACY, SAFETY",
author = "Knapen, {Lotte M.} and Koornstra, {Rutger H. T.} and Driessen, {Johanna H. M.} and {van Vlijmen}, Bas and Sander Croes and Stein Schalkwijk and Angela Colbers and Gerritsen, {Winald R.} and Burger, {David M.} and {de Vries}, Frank and {van Erp}, {Nielka P.}",
year = "2018",
month = "6",
doi = "10.1007/s11523-018-0564-3",
language = "English",
volume = "13",
pages = "363--370",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer, Cham",
number = "3",

}

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma : a Retrospective Cohort Study. / Knapen, Lotte M.; Koornstra, Rutger H. T.; Driessen, Johanna H. M.; van Vlijmen, Bas; Croes, Sander; Schalkwijk, Stein; Colbers, Angela; Gerritsen, Winald R.; Burger, David M.; de Vries, Frank; van Erp, Nielka P.

In: Targeted Oncology, Vol. 13, No. 3, 06.2018, p. 363-370.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma

T2 - a Retrospective Cohort Study

AU - Knapen, Lotte M.

AU - Koornstra, Rutger H. T.

AU - Driessen, Johanna H. M.

AU - van Vlijmen, Bas

AU - Croes, Sander

AU - Schalkwijk, Stein

AU - Colbers, Angela

AU - Gerritsen, Winald R.

AU - Burger, David M.

AU - de Vries, Frank

AU - van Erp, Nielka P.

PY - 2018/6

Y1 - 2018/6

KW - TUMOR RESPONSE

KW - OPEN-LABEL

KW - PHARMACOKINETICS

KW - TOLERANCE

KW - SURVIVAL

KW - EFFICACY

KW - SAFETY

U2 - 10.1007/s11523-018-0564-3

DO - 10.1007/s11523-018-0564-3

M3 - Article

VL - 13

SP - 363

EP - 370

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 3

ER -